EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance
ML Uribe, I Marrocco, Y Yarden - Cancers, 2021 - mdpi.com
Simple Summary Growth factors are hormone-like molecules able to promote division and
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …
migration of normal cells, but cancer captured the underlying mechanisms to unleash tumor …
[HTML][HTML] The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Objectives Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all
non-small cell lung cancer (NSCLC) patients and patient subgroups. Results A total of 456 …
non-small cell lung cancer (NSCLC) patients and patient subgroups. Results A total of 456 …
Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer
Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non–
small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors …
small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors …
[HTML][HTML] Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
JJ Chabon, AD Simmons, AF Lovejoy… - Nature …, 2016 - nature.com
Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here
we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell …
we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell …
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
A D'incecco, M Andreozzi, V Ludovini, E Rossi… - British journal of …, 2015 - nature.com
Background: Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1)
are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether …
are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether …
Molecular medicinal insights into scaffold hopping-based drug discovery success
Highlights•Molecular medicinal properties: Pharmacodynamics, physiochemical and
pharmacokinetic properties (P3-properties).•Successful innovation: Drug to drug, Drug to …
pharmacokinetic properties (P3-properties).•Successful innovation: Drug to drug, Drug to …
[HTML][HTML] International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of …
WD Travis, E Brambilla, M Noguchi… - Journal of thoracic …, 2011 - Elsevier
Introduction: Adenocarcinoma is the most common histologic type of lung cancer. To
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …
address advances in oncology, molecular biology, pathology, radiology, and surgery of lung …
[HTML][HTML] Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American …
NI Lindeman, PT Cagle, MB Beasley, DA Chitale… - Journal of Thoracic …, 2013 - Elsevier
Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …
An epithelial–mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR …
Purpose: Epithelial–mesenchymal transition (EMT) has been associated with metastatic
spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated a robust …
spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated a robust …
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically …
M Fukuoka, YL Wu, S Thongprasert… - Journal of clinical …, 2011 - ascopubs.org
Purpose The results of the Iressa Pan-Asia Study (IPASS), which compared gefitinib and
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …
carboplatin/paclitaxel in previously untreated never-smokers and light ex-smokers with …